Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients, Treatment and Monitoring
2.2. Statistical Analysis
3. Results
3.1. Features and Clinical Outcomes of the Patients
3.1.1. Baseline Systemic Inflammation Status and the Occurrence of Autoimmunity
3.1.2. Prognostic Influence of the Baseline Systemic Inflammation Status and the Occurrence of Autoimmunity in Patients Treated with PD-1-Blocking mAbs
3.1.3. Prognostic Relevance of irAEs in Patients Treated with PD-1-Blocking mAbs
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Xia, L.; Liu, Y.; Wang, Y. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Oncologist 2019, 24, S31–S41. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Feng, M.; Xiong, G.; Cao, Z.; Yang, G.; Zheng, S.; Song, X.; You, L.; Zheng, L.; Zhang, T.; Zhao, Y.; et al. PD-1/PD-L1 and immunotherapy for pancreatic cancer. Cancer Lett. 2017, 407, 57–65. [Google Scholar] [CrossRef] [PubMed]
- Friedman, C.F.; Proverbs-Singh, T.A.; Postow, M.A. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA Oncol. 2016, 2, 1346–1353. [Google Scholar] [CrossRef] [PubMed]
- Day, D.; Hansen, A.R. Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. BioDrugs 2016, 30, 571–584. [Google Scholar] [CrossRef] [PubMed]
- Naidoo, J.; Wang, X.; Woo, K.M.; Iyriboz, T.; Halpenny, D.; Cunningham, J.; Chaft, J.E.; Segal, N.H.; Callahan, M.K.; Lesokhin, A.M.; et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2017, 35, 709–717. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Giannicola, R.; D’Arrigo, G.; Botta, C.; Agostino, R.; Del Medico, P.; Falzea, A.C.; Barbieri, V.; Staropoli, N.; Del Giudice, T.; Pastina, P.; et al. Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab. Mol. Clin. Oncol. 2019, 11, 81–90. [Google Scholar] [CrossRef] [PubMed]
- Correale, P.; Saladino, R.E.; Giannarelli, D.; Sergi, A.; Mazzei, M.A.; Bianco, G.; Giannicola, R.; Iuliano, E.; Forte, I.M.; Calandruccio, N.D.; et al. HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis. Cells 2020, 9, 1964. [Google Scholar] [CrossRef]
- Fulop, T.; Kotb, R.; Fortin, C.F.; Pawelec, G.; De Angelis, F.; Larbi, A. Potential role of immunosenescence in cancer development. Ann. N. Y. Acad. Sci. 2010, 1197, 158–165. [Google Scholar] [CrossRef]
- Cusi, M.G.; Martorelli, B.; Di Genova, G.; Terrosi, C.; Campoccia, G.; Correale, P. Age related changes in T cell mediated immune response and effector memory to Respiratory Syncytial Virus (RSV) in healthy subjects. Immun. Ageing 2010, 7, 8–14. [Google Scholar] [CrossRef][Green Version]
- Hepper, H.J.; Sieber, C.; Walger, P.; Bahrmann, P.; Singler, K. Infections in the elderly. Crit. Care Clin. 2013, 29, 757–774. [Google Scholar] [CrossRef]
- Mutti, L.; Pentimalli, F.; Baglio, G.; Maiorano, P.; Saladino, R.E.; Correale, P.; Giordano, A. Coronavirus Disease (Covid-19): What Are We Learning in a Country With High Mortality Rate? Front. Immunol. 2020, 11, 11. [Google Scholar] [CrossRef]
- Ferrara, R.; Mezquita, L.; Auclin, E.; Chaput, N.; Besse, B. Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter? Cancer Treat. Rev. 2017, 60, 60–68. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Nosaki, K.; Saka, H.; Hosomi, Y.; Baas, P.; de Castro, G.; Reck, M.; Wu, Y.-L.; Brahmer, J.R.; Felip, E.; Sawada, T.; et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer 2019, 135, 188–195. [Google Scholar] [CrossRef]
- Correale, P.; Saladino, R.E.; Giannarelli, D.; Giannicola, R.; Agostino, R.; Staropoli, N.; Strangio, A.; Del Giudice, T.; Nardone, V.; Altomonte, M.; et al. Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade. J. Immunother. Cancer 2020, 8, e000733. [Google Scholar]
- Seymour, L.; Bogaerts, J.; Perrone, A.; Ford, R.; Schwartz, L.H.; Mandrekar, S.; Lin, N.U.; Litière, S.; Dancey, J.; Chen, A.; et al. iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017, 18, e143–e152. [Google Scholar] [CrossRef][Green Version]
- Cusi, M.G.; Botta, C.; Pastina, P.; Rossetti, M.G.; Dreassi, E.; Guidelli, G.M.; Fioravanti, A.; Martino, E.C.; Gandolfo, C.; Pagliuchi, M.; et al. Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients. Cancer Immunol. Immunother. 2015, 64, 1159–1173. [Google Scholar] [CrossRef] [PubMed]
- Correale, P.; Botta, C.; Martino, E.C.; Ulivieri, C.; Battaglia, G.; Carfagno, T.; Rossetti, M.G.; Fioravanti, A.; Guidelli, G.M.; Cheleschi, S.; et al. Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients. OncoImmunology 2015, 5, e1101205. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Pastina, P.; Nardone, V.; Botta, C.; Croci, S.; Tini, P.; Battaglia, G.; Ricci, V.; Cusi, M.G.; Gandolfo, C.; Misso, G.; et al. Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev). Oncotarget 2017, 8, 75904–75913. [Google Scholar] [CrossRef][Green Version]
- Martino, E.C.; Misso, G.; Pastina, P.; Costantini, S.; Vanni, F.; Gandolfo, C.; Botta, C.; Capone, F.; Lombardi, A.; Pirtoli, L.; et al. Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients. Cell Death Discov. 2016, 2, 16025. [Google Scholar] [CrossRef][Green Version]
- Elias, R.; Morales, J.; Presley, C. Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults. Curr. Oncol. Rep. 2017, 19, 62. [Google Scholar] [CrossRef]
- Muchnik, E.; Loh, K.P.; Strawderman, M.; Magnuson, A.; Mohile, S.G.; Estrah, V.; Maggiore, R.J. Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non–Small Cell Lung Cancer. J. Am. Geriatr. Soc. 2019, 67, 905–912. [Google Scholar] [CrossRef] [PubMed]
- Youn, B.; Trikalinos, N.A.; Mor, V.; Wilson, I.B.; Dahabreh, I.J. Real-world use and survival outcomes of immune checkpoint inhibitors in older adults with non–small cell lung cancer. Cancer 2019, 126, 978–985. [Google Scholar] [CrossRef] [PubMed]
- Tini, P.; Nardone, V.; Pastina, P.; Pirtoli, L.; Correale, P.; Giordano, A. The effects of radiotherapy on the survival of patients with unresectable non-small cell lung cancer. Expert Rev. Anticancer. Ther. 2018, 18, 593–602. [Google Scholar] [CrossRef] [PubMed]
- Yamaguchi, O.; Imai, H.; Minemura, H.; Suzuki, K.; Wasamoto, S.; Umeda, Y.; Osaki, T.; Kasahara, N.; Uchino, J.; Sugiyama, T.; et al. Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer. Cancer Chemother. Pharmacol. 2020, 85, 761–771. [Google Scholar] [CrossRef]
- Nikolich-Žugich, J. The twilight of immunity: Emerging concepts in aging of the immune system. Nat. Immunol. 2018, 19, 10–19. [Google Scholar] [CrossRef] [PubMed]
- Pang, H.; Wang, X.; Stinchcombe, T.E.; Wong, M.L.; Cheng, K.M.; Ganti, A.K.; Sargent, D.J.; Zhang, Y.; Hu, C.; Mandrekar, S.J.; et al. Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. J. Clin. Oncol. 2016, 34, 3992–3999. [Google Scholar] [CrossRef] [PubMed]
- Takamori, S.; Shimokawa, M.; Komiya, T. Prognostic impact of chronological age on efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: Real-world data from 86 173 patients. Thorac. Cancer 2021, 12, 2943–2948. [Google Scholar] [CrossRef]
- Morimoto, K.; Yamada, T.; Yokoi, T.; Kijima, T.; Goto, Y.; Nakao, A.; Hibino, M.; Takeda, T.; Yamaguchi, H.; Takumi, C.; et al. Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer. Lung Cancer 2021, 161, 26–33. [Google Scholar] [CrossRef]
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- Thompson, J.C.; Hwang, W.-T.; Davis, C.; Deshpande, C.; Jeffries, S.; Rajpurohit, Y.; Krishna, V.; Smirnov, A.; Verona, R.; Lorenzi, M.V.; et al. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy. Lung Cancer 2020, 139, 1–8. [Google Scholar] [CrossRef]
- Danaher, P.; Warren, S.; Lu, R.; Samayoa, J.; Sullivan, A.; Pekker, I.; Wallden, B.; Marincola, F.M.; Cesano, A. Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): Results from The Cancer Genome Atlas (TCGA). J. Immunother. Cancer 2018, 6, 63. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Liu, C.; Zheng, S.; Jin, R.; Wang, X.; Wang, F.; Zang, R.; Xu, H.; Lu, Z.; Huang, J.; Lei, Y.; et al. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Lett. 2020, 470, 95–105. [Google Scholar] [CrossRef] [PubMed]
- Bar, N.; Costa, F.; Das, R.; Duffy, A.; Samur, M.; McCachren, S.; Gettinger, S.N.; Neparidze, N.; Parker, T.L.; Bailur, J.K.; et al. Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. JCI Insight 2020, 5, 129353. [Google Scholar] [CrossRef]
- Correale, P.; Botta, C.; Staropoli, N.; Nardone, V.; Pastina, P.; Ulivieri, C.; Gandolfo, C.; Baldari, T.C.; Lazzi, S.; Ciliberto, D.; et al. Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine. Oncotarget 2018, 9, 20539–20554. [Google Scholar] [CrossRef] [PubMed]
- Hakozaki, T.; Richard, C.; Elkrief, A.; Hosomi, Y.; Benlaïfaoui, M.; Mimpen, I.; Terrisse, S.; DeRosa, L.; Zitvogel, L.; Routy, B.; et al. The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer. Cancer Immunol. Res. 2020, 8, 1243–1250. [Google Scholar] [CrossRef] [PubMed]
- Shaikh, F.Y.; Gills, J.J.; Sears, C.L. Impact of the microbiome on checkpoint inhibitor treatment in patients with non-small cell lung cancer and melanoma. EBioMedicine 2019, 48, 642–647. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Vogl, T.; Klompus, S.; Leviatan, S.; Kalka, I.N.; Weinberger, A.; Wijmenga, C.; Fu, J.; Zhernakova, A.; Weersma, R.K.; Segal, E. Population-wide diversity and stability of serum antibody epitope repertoires against human microbiota. Nat. Med. 2021, 27, 1442–1450. [Google Scholar] [CrossRef] [PubMed]
- Cui, M.; Trimigno, A.; Aru, V.; Rasmussen, M.A.; Khakimov, B.; Engelsen, S.B. Influence of Age, Sex, and Diet on the Human Fecal Metabolome Investigated by 1H NMR Spectroscopy. J. Proteome Res. 2021, 20, 3642–3653. [Google Scholar] [CrossRef] [PubMed]
- Garner, H.; De Visser, K.E. Immune crosstalk in cancer progression and metastatic spread: A complex conversation. Nat. Rev. Immunol. 2020, 20, 483–497. [Google Scholar] [CrossRef]
- Jiang, X.; Wang, J.; Deng, X.; Xiong, F.; Ge, J.; Xiang, B.; Wu, X.; Ma, J.; Zhou, M.; Li, X.; et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol. Cancer 2019, 18, 1–17. [Google Scholar] [CrossRef][Green Version]
- Nardone, V.; Giannicola, R.; Bianco, G.; Giannarelli, D.; Tini, P.; Pastina, P.; Falzea, A.C.; Macheda, S.; Caraglia, M.; Luce, A.; et al. Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade. Front. Oncol. 2021, 11, 2193. [Google Scholar] [CrossRef]
- Nardone, V.; Pastina, P.; Giannicola, R.; Agostino, R.; Croci, S.; Tini, P.; Pirtoli, L.; Giordano, A.; Tagliaferri, P.; Correale, P. How to Increase the Efficacy of Immunotherapy in NSCLC and HNSCC: Role of Radiation Therapy, Chemotherapy, and Other Strategies. Front. Immunol. 2018, 9, 2941. [Google Scholar] [CrossRef] [PubMed]
- Correale, P.; Saladino, R.E.; Nardone, V.; Giannicola, R.; Agostino, R.; Pirtoli, L.; Caraglia, M.; Botta, C.; Tagliaferri, P. Could PD-1/PDL1 immune checkpoints be linked to HLA signature? Immunotherapy 2019, 11, 1523–1526. [Google Scholar] [CrossRef]
- Grieshober, L.; Graw, S.; Barnett, M.J.; Goodman, G.E.; Chen, C.; Koestler, D.C.; Marsit, C.J.; Doherty, J.A. Pre-diagnosis neutrophil-to-lymphocyte ratio and mortality in individuals who develop lung cancer. Cancer Causes Control. 2021, 32, 1227–1236. [Google Scholar] [CrossRef] [PubMed]
- Seber, S.; Bayir, D.; Yetisyigit, T. Prognostic values of various hematological variables as markers of systemic inflammation in metastatic lung cancer. J. Cancer Res. Ther. 2020, 16, 731. [Google Scholar] [CrossRef]
- Huang, Z.; Xing, S.; Zhu, Y.; Qu, Y.; Jiang, L.; Sheng, J.; Wang, Q.; Xu, S.; Xue, N. Establishment and Validation of Nomogram Model Integrated With Inflammation-Based Factors for the Prognosis of Advanced Non-Small Cell Lung Cancer. Technol. Cancer Res. Treat. 2020, 19, 1533033820971605. [Google Scholar] [CrossRef]
- Biswas, T.; Kang, K.; Gawdi, R.; Bajor, D.; Machtay, M.; Jindal, C.; Efird, J. Using the Systemic Immune-Inflammation Index (SII) as a Mid-Treatment Marker for Survival among Patients with Stage-III Locally Advanced Non-Small Cell Lung Cancer (NSCLC). Int. J. Environ. Res. Public Heal. 2020, 17, 7995. [Google Scholar] [CrossRef] [PubMed]
- Davizon-Castillo, P.; McMahon, B.; Aguila, S.; Bark, D.; Ashworth, K.; Allawzi, A.; Campbell, R.A.; Montenont, E.; Nemkov, T.; D’Alessandro, A.; et al. TNF-α–driven inflammation and mitochondrial dysfunction define the platelet hyperreactivity of aging. Blood 2019, 134, 727–740. [Google Scholar] [CrossRef]
- Bergholt, N.L.; Olesen, M.L.; Foldager, C.B. Age-Dependent Systemic Effects of a Systemic Intermittent Hypoxic Therapy In Vivo. High Alt. Med. Biol. 2019, 20, 221–230. [Google Scholar] [CrossRef] [PubMed]
- Palomar-Abril, V.; Comes, T.S.; Campos, S.T.; Ureste, M.M.; Bosch, V.G.; Maiques, I.C.M. Impact of Age on Inflammation-Based Scores among Patients Diagnosed with Stage III Non-Small Cell Lung Cancer. Oncology 2020, 98, 528–533. [Google Scholar] [CrossRef]
- Vareki, S.M. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J. Immunother. Cancer 2018, 6, 157. [Google Scholar] [CrossRef] [PubMed]
- Bonaventura, P.; Shekarian, T.; Alcazer, V.; Valladeau-Guilemond, J.; Valsesia-Wittmann, S.; Amigorena, S.; Caux, C.; Depil, S. Cold Tumors: A Therapeutic Challenge for Immunotherapy. Front. Immunol. 2019, 10, 168. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Chen, D.S.; Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 2017, 541, 321–330. [Google Scholar] [CrossRef]
- Läubli, H.; Koelzer, V.H.; Matter, M.S.; Herzig, P.; Schlienger, B.D.; Wiese, M.N.; Lardinois, D.; Mertz, K.; Zippelius, A. The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors. OncoImmunology 2017, 7, e1386362. [Google Scholar] [CrossRef]
- Fiala, O.; Sorejs, O.; Sustr, J.; Kucera, R.; Topolcan, O.; Finek, J. Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors. Anticancer. Res. 2020, 40, 1219–1227. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Correale, P.; Tagliaferri, P.; Fioravanti, A.; Del Vecchio, M.T.; Remondo, C.; Montagnani, F.; Rotundo, M.S.; Ginanneschi, C.; Martellucci, I.; Francini, E.; et al. Immunity Feedback and Clinical Outcome in Colon Cancer Patients Undergoing Chemoimmunotherapy with Gemcitabine + FOLFOX followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Aldesleukin (GOLFIG-1 Trial). Clin. Cancer Res. 2008, 14, 4192–4199. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Correale, P.; Fioravanti, A.; Bertoldi, I.; Montagnani, F.; Miracco, C.; Francini, G. Occurrence of Autoimmunity in a Long-Term Survivor with Metastatic Colon Carcinoma Treated with a New Chemo-Immunotherapy Regimen. J. Chemother. 2008, 20, 278–281. [Google Scholar] [CrossRef]
- Nardone, V.; Tini, P.; Pastina, P.; Botta, C.; Reginelli, A.; Carbone, S.; Giannicola, R.; Calabrese, G.; Tebala, C.; Guida, C.; et al. Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab. Oncol. Lett. 2019, 19, 1559–1566. [Google Scholar] [CrossRef]
Parameters | Younger Patient Cohort (Age ≤ 74) | Older Patient Cohort (Age ≥ 75) | p-Values |
---|---|---|---|
Neutrophils | 5.3 ± 3.5 | 4.6 ± 2.3 | 0.59 |
Lymphocytes | 2.9 ± 10.4 | 1.4 ± 0.7 | 0.23 |
NLR | 3.8 ± 3.7 | 3.5 ± 2.3 | 0.39 |
CRP | 26.9 ± 42.7 | 18.8 ± 30.7 | 0.52 |
ESR | 47.2 ± 31.8 | 49.7 ± 33.4 | 0.29 |
LDH | 402.8 ± 286.7 | 373.3 ± 227.1 | 0.24 |
PCT | 0.22 ± 0.50 | 0.1 ± 0.1 | 0.86 |
∆Neutrophils | 7.5 ± 20.1 | 4.5 ± 9.1 | 0.18 |
∆Lymphocytes | 1.5 ± 4.9 | 2.7 ± 4.6 | 0.23 |
∆NLR | 8.5 ± 14.3 | 5.5 ± 7.2 | 0.06 |
∆CRP | 10.2 ± 20.6 | 25.6 ± 71.7 | 0.14 |
∆ESR | 8.8 ± 20.4 | 8.8 ± 21.9 | 0.14 |
∆LDH | 2.7 ± 5.3 | 1.8 ± 5.1 | 0.70 |
∆PCT | 7.3 ± 12.2 | 5.4 ± 6.9 | 0.54 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nardone, V.; Giannicola, R.; Giannarelli, D.; Saladino, R.E.; Azzarello, D.; Romeo, C.; Bianco, G.; Rizzo, M.R.; Di Meo, I.; Nesci, A.; Pastina, P.; Falzea, A.C.; Caracciolo, D.; Reginelli, A.; Caraglia, M.; Luce, A.; Mutti, L.; Giordano, A.; Cappabianca, S.; Pirtoli, L.; Barbieri, V.; Tassone, P.; Tagliaferri, P.; Correale, P. Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis. Life 2021, 11, 1235. https://doi.org/10.3390/life11111235
Nardone V, Giannicola R, Giannarelli D, Saladino RE, Azzarello D, Romeo C, Bianco G, Rizzo MR, Di Meo I, Nesci A, Pastina P, Falzea AC, Caracciolo D, Reginelli A, Caraglia M, Luce A, Mutti L, Giordano A, Cappabianca S, Pirtoli L, Barbieri V, Tassone P, Tagliaferri P, Correale P. Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis. Life. 2021; 11(11):1235. https://doi.org/10.3390/life11111235
Chicago/Turabian StyleNardone, Valerio, Rocco Giannicola, Diana Giannarelli, Rita Emilena Saladino, Domenico Azzarello, Caterina Romeo, Giovanna Bianco, Maria Rosaria Rizzo, Irene Di Meo, Antonio Nesci, Pierpaolo Pastina, Antonia Consuelo Falzea, Daniele Caracciolo, Alfonso Reginelli, Michele Caraglia, Amalia Luce, Luciano Mutti, Antonio Giordano, Salvatore Cappabianca, Luigi Pirtoli, Vito Barbieri, Pierfrancesco Tassone, Pierosandro Tagliaferri, and Pierpaolo Correale. 2021. "Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis" Life 11, no. 11: 1235. https://doi.org/10.3390/life11111235